Size matters: The prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia

Haematologica

Volumn 91, Issue 7, 2006, Pages 952-955

  Fourouclas, Nasios ^a   Campbell, Peter J ^a   Bench, Anthony J ^a   Swanton, Soheila ^a   Baxter, E Joanna ^a   Huntly, Brian J P ^a   Green, Anthony R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Chronic myeloid leukemia; Derivative 9 chromosome; Large deletions

Indexed keywords

ARTICLE; CHROMOSOME 9; CHROMOSOME DELETION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; PHILADELPHIA 1 CHROMOSOME; SURVIVAL;

CHROMOSOMES, HUMAN, PAIR 9; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MODELS, GENETIC; PROGNOSIS; SEQUENCE DELETION;

EID: 33745765411     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Bartram CR, de Klein A, Hagemeijer A, Van Agthoven T, Van Kessel AG, Bootsma D, et al. Translocation of the c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelotic leukemia. Nature 1983;306:277-80.
2. Rowley DJ. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giesma staining. Nature 1973;243:290-3.
3. Sinclair PB, Green AR, Grace C, Nacheva EP. Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. Blood 1997;90:1395-402.
4. Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000;95:738-44.
5. Huntly BJP, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001;98:1732-8.
6. Kolomietz E, Al-Maghradi J, Brennan S, Karaskova J, Minkin S, Lipton J, et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 2001;97:3581-8.
7. Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G, et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Gen Cytogen 2001;128:114-9.
8. Huntly BJP, Bench AJ, Delabesse E, Reid AG, Li J, Scott MA, et al. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood 2002;99:4547-53.
9. Huntly BJP, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003;102:1160-8.
10. Loncarevic I, Romer J, Starke H, Heller A, Bleck C, Ziegler M, et al. Heterogenic molecular basis for loss of ABL1-CR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia. Genes Chromosomes Cancer 2002;34:193-200.
11. de la Fuente J, Merx K, Steer J, Muller M, Szydlo RM, Maywald O, et al. ABL-BCR expression does not correlate with deletions of the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood 2001;98:2879-80.
12. Storlazzi CT, Specchia G, Anelli L, Albano F, Pastore D, Zagaria A, et al. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. Genes, Chromosomes and Cancer 2002;3:271-6.
13. Huntly BJP, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C, et al. Imatinib improves but may not fully reverse the poor prognosis of CML patients with derivative chromosome 9 deletions. Blood 2003;102:2205-12.
14. Quintas-Cardama A, Katarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005;105:2281-6.
15. O'Brien SG, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N Engl J Med 2003;348:994-1004.
16. Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982;38:163-70.
17. Grand F, Kulkarni S, Chase A, Goldman JM, Gordon M, Cross NCP. Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia. Cancer Res 1999;59:3870-4.